Successful desensitisation to paclitaxel with omalizumab

Area of Science:

• Oncology
• Allergy and Immunology
• Pharmacology

Background:

• Paclitaxel is a crucial chemotherapy agent for triple-negative breast cancer.
• Hypersensitivity reactions, including anaphylaxis, can complicate paclitaxel treatment.
• Standard rapid drug desensitization (RDD) protocols may not always be successful.

Observation:

• A young female patient with triple-negative breast cancer developed anaphylaxis during paclitaxel chemotherapy.
• Initial attempts at rapid drug desensitization (RDD) for paclitaxel were unsuccessful.
• The patient experienced severe allergic symptoms, including dyspnea and angioedema.

Findings:

• Off-label administration of omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, preceded a subsequent RDD attempt.
• The patient tolerated the full dose of paclitaxel chemotherapy after omalizumab pre-treatment and successful desensitization.
• Omalizumab facilitated successful paclitaxel infusion, enabling completion of chemotherapy.

Implications:

• Omalizumab may serve as an effective adjuvant therapy for patients experiencing hypersensitivity reactions to paclitaxel.
• This approach could improve chemotherapy adherence and treatment outcomes in hypersensitive cancer patients.
• Further research is warranted to establish the role of omalizumab in managing chemotherapy-induced hypersensitivity.